| Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec |
2019-11-12 |
| NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform |
2019-11-07 |
| A2 Biotherapeutics–SEVERAL: investment, 201911 emerges from stealh with financing round Series A $57m |
2019-11-05 |
| Celonis–SEVERAL: investment, 201911 financing round Series C $290m |
2019-11-01 |
| Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
| NikYang Enterprises–Labforward: electonic lab notebook, 201910 collab existent NikYank Enterprises Ltd is Chinese partner of Labforward GmbH |
2019-10-24 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments |
2019-10-21 |
| Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
| Avacta–SEVERAL: investment, 201910– proposed placing + subscription up to £9m with 59.8m nrew ordinary shares at 15p/share |
2019-10-18 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m |
2019-10-17 |
| Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico |
2019-10-16 |
| CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
| FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
| Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data |
2019-10-09 |
| Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan |
2019-10-04 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug RnD + commercialisation |
2019-10-01 |
| Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters |
2019-09-30 |
| STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings |
2019-09-30 |
| Tacalyx–SEVERAL: investment, 201909 seed financing round €7m co-led by BIVF + Kurma Partners |
2019-09-25 |
| Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications |
2019-09-24 |
| Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery |
2019-09-20 |
| Bruker–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research |
2019-09-20 |
| Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures |
2019-09-18 |
| Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB |
2019-09-18 |
| Belyntic–SEVERAL: investment, 201909 seed financing round €1.3m led by IBB + incl HTGF + business angel Till Knorr |
2019-09-16 |
| Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures |
2019-09-12 |
| Khanu Management–SEVERAL: investment, 201909 1st closing €60m of KHAN Technology Transfer Fund I |
2019-09-12 |
| Bayer–Minapharm: GlymaxX technology, 201909– license for use in cell line developm for cancer antibody candidate of Bayer |
2019-09-10 |
| Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America |
2019-09-10 |
| BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market |
2019-09-09 |
| Curetis–HC Wainwright: investor conference, 201908 supply service Curetis presents at HC Wainwright Global Life Sciences Conference in NY |
2019-09-08 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| iStar Medical–SEVERAL: investment, 201905 financing round Series C €40m led by LSP + Gimv |
2019-09-05 |
| PathoQuest–SEVERAL: investment, 201909 financing round €7.57m incl venture loan from Norgine Ventures |
2019-09-05 |
| BioNTech–Gates Foundation: investment, 201909 equity investment $55m in connection with anti-infectives collaboration |
2019-09-04 |
| Boehringer–Lupin: MEK inhibitor, 201909– license $20m upfront + $700m milestones + royalties to LNP3794 for combi with KRAS inhibitors for cancer |
2019-09-04 |
| Gates Foundation–BioNTech: anti-infectives, 201909– collab developm of HIV + TB immunotherapies with up to $100m funding incl equity investment $55m |
2019-09-04 |
| Celgene–Immatics: cell therapy, 201908– strategic collab + excl option $75m upfront + $1.5b milestones + royalties for three TCR-T targets |
2019-08-28 |
| ADC Therapeutics–Freenome: pharmacodiagnostics, 201908– collab developm multiomics biomarker for ADCT-402 treatment in DLBCL |
2019-08-26 |
| Merck (US)–Themis Bioscience: vaccine technology, 201908– collab research + license for use of MV technology platform for vaccine development |
2019-08-22 |
| Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors |
2019-08-21 |
| Araris Biotech–SEVERAL: investment, 201908 seed financing round CHF2.5m with Redalpine + Schroder Adveq + VI Partners |
2019-08-20 |
| Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares |
2019-08-20 |
| Synpromics–AskBio: investment, 201908 acquisition of Synpromics Ltd by Asklepios Biopharmaceutical Inc |
2019-08-13 |
| Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual RnD center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists |
2019-08-12 |
| LemnaTec–Nynomic: investment, 201908 acquisition €na of assets of bankrupt LemnaTec Gmbh by Nynomic AG |
2019-08-12 |
| Biognosys–SEVERAL: investment, 201908 financing round Series G from existing + new institutional + private investors |
2019-08-08 |
| BSSN Software–Merck (DE): investment, 201908 acquisition €na of BSSN Software GmbH by Merck KGaA |
2019-08-06 |
| Platomics–SEVERAL: investment, 201908 investment €7-digit from undisclosed investors |
2019-08-06 |
| Inveox–SEVERAL: investment, 201908 3rd financing round €17m |
2019-08-05 |
| Babylon Health–SEVERAL: investment, 201908 financing round $550m from existing + new investors |
2019-08-02 |
| Immunic–Germany (govt): grant, 201908–202207 BMBF grant €654k to support German-Japanese research project with InnoMuNIiCH project |
2019-08-01 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Quanta Dialysis Technologies–SEVERAL: investment, 201907 financing round Series C £38m led by Swiss family office + btov Partners |
2019-07-29 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| EverlyWell–PerkinElmer: consumer diagnostics, 201907– collab + supply CAP lab services immunoassays + genomic tests for US home health test market |
2019-07-24 |
| Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund |
2019-07-24 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties |
2019-07-18 |
| MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for RnD by Broad |
2019-07-18 |
| Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer |
2019-07-17 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Amal Therapeutics–Boehringer: investment, 201907 acquisition of Amal by Boehringer for up to €325m |
2019-07-15 |
| Ncardia–Evotec: investment, 201907 acquisition €na of iPSC assets + 17 strong team of bankrupt Ncardia AG in Cologne |
2019-07-15 |
| BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by Fidelity ./. €87.7m delayed as of 9/19 |
2019-07-09 |
| Breakpoint Therapeutics–SEVERAL: investment, 201907 first financing round €30m for spin-out from Evotec led by Medicxi + incl Taiho Ventures + Evotec |
2019-07-08 |
| PMOD Technologies–Bruker: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker |
2019-07-08 |
| Pantherna Therapeutics–SEVERAL: investment, 201907 seed financing round €3.5m from HTGF + Detlev Riesner + EIF + State of Brandenburg |
2019-07-03 |
| Boehringer–Yuhan: GLP1R/FGF21R agonist, 201907– collab + license agreem for FGF21 $40m upfront + $830m milestones + royalties |
2019-07-01 |
| Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI |
2019-07-01 |
| ExpreS2ion Biotech–ERS Genomics: CRISPR technology, 201907– license non-excl €na for use + commercialisation of products from ERS Genomics |
2019-07-01 |
| CryoTherapeutics–SEVERAL: investment, 201906 financing round Series B €7m incl equity + debt + non-dilutive cash advances |
2019-06-27 |
| Modag–SEVERAL: investment, 201906 financing round Series A €12m led by Massa Investment AG |
2019-06-27 |
| PhagoMed–SEVERAL: investment, 201906 2nd financing round €1.5m from existing + new investors |
2019-06-27 |
| Evotec–SEVERAL: credit, 201906– promissory note €250m with lead arrangers Deutsche Bank + LBBW |
2019-06-26 |
| Allergan–AbbVie: investment, 201905– acquisition $63b in cash + shares by AbbVie ANNOUNCED |
2019-06-25 |
| Osteolabs–SEVERAL: investment, 201906 seed financing round from MGB Kiel + MVZ Dr Krause Kiel + two business angels |
2019-06-17 |
| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
| Bruker–Leucadia: investor conference, 201906 supply service Bruker presents at Jefferies Healthcare Conference in New York |
2019-06-06 |
| Evotec–Leucadia: investor conference, 201906 supply service Evotec AG presents at Jefferies 2019 Global Healthcare Conference NYC |
2019-06-06 |
| HighChem–Thermo Fisher: investment, 201906 acquisition €na of HighChem Ltd by Thermo Fisher |
2019-06-06 |
| Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products |
2019-06-06 |
| Evotec–Deutsche Bank: investor conference, 201906 supply service Evotec presents at dbAccess Berlin Conference |
2019-06-05 |
| MiniFab–Schott: investment, 201906– acquisition of MiniFab Pty Ltd by Schott |
2019-06-05 |
| Medigene–Leucadia: investor conference, 201906 supply service Medigene presents at Jefferies Global Healthcare Conference NY |
2019-06-04 |
| Bruker–908 Devices: sample separation technology, 201906– collab integration of ZipChip microfluidics separation with Bruker TOF systems |
2019-06-03 |
| Vedere Bio–SEVERAL: investment, 201906 financing round Series A $21m |
2019-06-01 |
| Bayer–Roche: molecular companion diagnostics, 201905– collab ww €na developm + commercialisation o fNGS-based CDx in oncology |
2019-05-29 |
| PHW-Gruppe–Ampersand: investment, 201905 acquisition of Vibalogics GmbH by Ampersand Capital Partners |
2019-05-29 |
| Biocrates–NONE: investment, 201905– bankruptcy filed for subsidiary Metanomics Health GmbH |
2019-05-22 |
| Cubuslab–Labfolder: investment, 201905 acquisition merger of Cubuslab Gmbh + Labfolder GmbH + new name Labforward GmbH |
2019-05-22 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
